ProQR Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
AX-0810 is advancing in cholestatic diseases with key data expected soon and biliary atresia as the lead phase II indication. Next-gen programs like AX-0811 and AX-0422 show strong preclinical results, while AI-driven discovery and strategic partnerships support a robust pipeline and financial runway into mid-2027.
-
The company is advancing its proprietary RNA editing platform, with lead program AX-0810 in phase I for cholestatic diseases and additional candidates in Rett syndrome and fatty liver disease. Key data readouts and milestones are expected in 2024, supported by a strong cash position and strategic partnerships.
Fiscal Year 2025
-
The company is advancing RNA editing therapies, highlighted by a lead program for cholestatic diseases with a phase 1 trial underway and initial data expected soon. Indication selection for phase 2 will follow, and a Rett syndrome program is progressing toward clinical candidate selection.
-
AX-0810, a first-in-class RNA editing therapy targeting NTCP, has entered phase I trials in healthy volunteers to address cholestatic diseases. The study uses robust biomarker strategies to assess target engagement and safety, with initial data expected by year-end and patient cohorts planned for PSC.
-
Panelists highlighted rapid clinical progress in ADAR RNA editing, with lead programs in AATD showing durable, physiologically relevant protein correction and new targets like NTCP and PNPLA3 advancing. The field is maturing quickly, with robust chemistry, delivery, and target selection strategies supporting broad future applications.
-
A novel RNA editing platform is advancing toward clinical trials, with a lead program targeting cholestatic liver diseases and several additional programs in cardiovascular, CNS, and metabolic indications. Strategic partnerships and a strong cash position support a robust pipeline and anticipated clinical milestones this year.
Fiscal Year 2024
-
The event highlighted significant progress in RNA editing platform development, robust financials, and strategic partnerships. Key pipeline programs are advancing toward clinical trials, with major readouts expected in 2025 and 2026.
-
Axiomer, an RNA editing platform, is advancing two lead programs for cholestatic and cardiovascular diseases, with clinical entry targeted for late 2024 or early 2025. Key biomarker and delivery decisions will be announced alongside updated data, while a major partnership with Eli Lilly supports expansion into CNS indications.